Skip to main content

Table 1 (abstract A14). Characteristics of Physician Management of JSpA Patients (n=60)

From: Proceedings of the 2019 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Annual Scientific Meeting

  N (%)
Practice Location
 Academic 55 (91)
 Private 4 (7)
Years in practice  
 <5 years 18 (30)
 5-10 years 17 (28)
 11-15 years 9 (15)
 > 15 years 16 (27)
Training  
 Pediatric Rheumatologist 56 (93)
 Med/Peds Rheumatologist 3 (5)
 Other 1 (2)
Number of JSpA patients seen annually  
 < 5 patients 5 (8)
 5-10 patients 16 (27)
 >10 patients 39 (65)
Duration before deeming treatment failure  
 2 months 4 (7)
 3 months 36 (60)
 6 months 14 (23)
Have JSpA patients who failed TNFi therapy in last 2 yrs 38 (63)
Have switched back to same TNFi after failing 10 (17)
Reasons for change anti-TNF therapy:  
 Secondary non-response 43 (72)
 Primary non-response 35 (58)
 Intolerance 29 (48)
 Concomitant disease 28 (47)
 Chronic pain 15 (25)
Reasons for primary non-response  
 Arthritis (Sacroiliac joints) 27 (45)
 Arthritis (peripheral) 16 (27)
 Enthesitis 16 (27)
 Pain 2 (1)
Number of anti-TNF agents (total) tried before switching to another class  
 1 1 (1.5)
 2 37 (62)
 3 21(35)
 >3 1 (1.5)
Other medications used after TNFi failure  
 Abatacept 24 (40)
 Tocilizumab 21 (35)
 Ustekinumab 17 (28)
 Secukinumab 16 (27)
 Tofacitinib 8 (13)
 Rituximab 2 (3)
 Other: Apremilast (1), Methotrexate (1), Steroids (1)